Free Trial
→ I was right about SpaceX (From Brownstone Research) (Ad)tc pixel Free MDLN Stock Alerts

Medline (MDLN) Competitors

Medline logo
$34.47 +1.28 (+3.86%)
Closing price 06/3/2026 04:00 PM Eastern
Extended Trading
$34.58 +0.12 (+0.33%)
As of 08:56 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

MDLN vs. GEHC, PHG, ZBH, SOLV, and SNN

Should you buy Medline stock or one of its competitors? MarketBeat compares Medline with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Medline include GE HealthCare Technologies (GEHC), Koninklijke Philips (PHG), Zimmer Biomet (ZBH), Solventum (SOLV), and Smith & Nephew SNATS (SNN). These companies are all part of the "medical equipment" industry.

How does Medline compare to GE HealthCare Technologies?

GE HealthCare Technologies (NASDAQ:GEHC) and Medline (NASDAQ:MDLN) are both large-cap medical equipment companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.

In the previous week, GE HealthCare Technologies had 4 more articles in the media than Medline. MarketBeat recorded 15 mentions for GE HealthCare Technologies and 11 mentions for Medline. GE HealthCare Technologies' average media sentiment score of 1.01 beat Medline's score of 0.46 indicating that GE HealthCare Technologies is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
GE HealthCare Technologies
7 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Medline
2 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

GE HealthCare Technologies has higher earnings, but lower revenue than Medline.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GE HealthCare Technologies$20.63B1.37$2.08B$4.1814.84
Medline$28.43B1.59N/AN/AN/A

GE HealthCare Technologies has a net margin of 9.10% compared to Medline's net margin of 0.00%. GE HealthCare Technologies' return on equity of 20.46% beat Medline's return on equity.

Company Net Margins Return on Equity Return on Assets
GE HealthCare Technologies9.10% 20.46% 5.73%
Medline N/A N/A N/A

GE HealthCare Technologies currently has a consensus target price of $80.21, suggesting a potential upside of 29.31%. Medline has a consensus target price of $50.54, suggesting a potential upside of 46.62%. Given Medline's stronger consensus rating and higher probable upside, analysts clearly believe Medline is more favorable than GE HealthCare Technologies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GE HealthCare Technologies
0 Sell rating(s)
9 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.50
Medline
1 Sell rating(s)
5 Hold rating(s)
22 Buy rating(s)
1 Strong Buy rating(s)
2.79

82.1% of GE HealthCare Technologies shares are owned by institutional investors. 0.4% of GE HealthCare Technologies shares are owned by company insiders. Comparatively, 0.8% of Medline shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Medline beats GE HealthCare Technologies on 7 of the 13 factors compared between the two stocks.

How does Medline compare to Koninklijke Philips?

Medline (NASDAQ:MDLN) and Koninklijke Philips (NYSE:PHG) are both large-cap medical equipment companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

In the previous week, Medline had 7 more articles in the media than Koninklijke Philips. MarketBeat recorded 11 mentions for Medline and 4 mentions for Koninklijke Philips. Medline's average media sentiment score of 0.46 beat Koninklijke Philips' score of 0.40 indicating that Medline is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Medline
2 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Koninklijke Philips
0 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Medline currently has a consensus target price of $50.54, indicating a potential upside of 46.62%. Given Medline's stronger consensus rating and higher probable upside, equities analysts plainly believe Medline is more favorable than Koninklijke Philips.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Medline
1 Sell rating(s)
5 Hold rating(s)
22 Buy rating(s)
1 Strong Buy rating(s)
2.79
Koninklijke Philips
0 Sell rating(s)
4 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

13.7% of Koninklijke Philips shares are owned by institutional investors. 0.8% of Medline shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Koninklijke Philips has lower revenue, but higher earnings than Medline.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medline$28.43B1.59N/AN/AN/A
Koninklijke Philips$20.17B1.21$1.01B$1.1721.67

Koninklijke Philips has a net margin of 5.49% compared to Medline's net margin of 0.00%. Koninklijke Philips' return on equity of 13.51% beat Medline's return on equity.

Company Net Margins Return on Equity Return on Assets
MedlineN/A N/A N/A
Koninklijke Philips 5.49%13.51%5.48%

Summary

Medline beats Koninklijke Philips on 9 of the 13 factors compared between the two stocks.

How does Medline compare to Zimmer Biomet?

Zimmer Biomet (NYSE:ZBH) and Medline (NASDAQ:MDLN) are both large-cap medical equipment companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

In the previous week, Zimmer Biomet had 7 more articles in the media than Medline. MarketBeat recorded 18 mentions for Zimmer Biomet and 11 mentions for Medline. Zimmer Biomet's average media sentiment score of 0.93 beat Medline's score of 0.46 indicating that Zimmer Biomet is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Zimmer Biomet
12 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Medline
2 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

88.9% of Zimmer Biomet shares are held by institutional investors. 1.3% of Zimmer Biomet shares are held by company insiders. Comparatively, 0.8% of Medline shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Zimmer Biomet currently has a consensus price target of $102.70, suggesting a potential upside of 20.66%. Medline has a consensus price target of $50.54, suggesting a potential upside of 46.62%. Given Medline's stronger consensus rating and higher probable upside, analysts clearly believe Medline is more favorable than Zimmer Biomet.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zimmer Biomet
3 Sell rating(s)
12 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.26
Medline
1 Sell rating(s)
5 Hold rating(s)
22 Buy rating(s)
1 Strong Buy rating(s)
2.79

Zimmer Biomet has higher earnings, but lower revenue than Medline.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zimmer Biomet$8.23B2.00$705.20M$3.8522.11
Medline$28.43B1.59N/AN/AN/A

Zimmer Biomet has a net margin of 9.05% compared to Medline's net margin of 0.00%. Zimmer Biomet's return on equity of 13.24% beat Medline's return on equity.

Company Net Margins Return on Equity Return on Assets
Zimmer Biomet9.05% 13.24% 7.28%
Medline N/A N/A N/A

Summary

Zimmer Biomet beats Medline on 8 of the 12 factors compared between the two stocks.

How does Medline compare to Solventum?

Solventum (NYSE:SOLV) and Medline (NASDAQ:MDLN) are both large-cap medical equipment companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

In the previous week, Medline had 8 more articles in the media than Solventum. MarketBeat recorded 11 mentions for Medline and 3 mentions for Solventum. Medline's average media sentiment score of 0.46 beat Solventum's score of 0.25 indicating that Medline is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Solventum
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Medline
2 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Solventum currently has a consensus price target of $84.25, indicating a potential upside of 7.47%. Medline has a consensus price target of $50.54, indicating a potential upside of 46.62%. Given Medline's stronger consensus rating and higher probable upside, analysts clearly believe Medline is more favorable than Solventum.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Solventum
1 Sell rating(s)
5 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.50
Medline
1 Sell rating(s)
5 Hold rating(s)
22 Buy rating(s)
1 Strong Buy rating(s)
2.79

Solventum has higher earnings, but lower revenue than Medline.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Solventum$8.33B1.63$1.56B$8.169.61
Medline$28.43B1.59N/AN/AN/A

Solventum has a net margin of 17.33% compared to Medline's net margin of 0.00%. Solventum's return on equity of 23.51% beat Medline's return on equity.

Company Net Margins Return on Equity Return on Assets
Solventum17.33% 23.51% 7.63%
Medline N/A N/A N/A

Summary

Medline beats Solventum on 7 of the 11 factors compared between the two stocks.

How does Medline compare to Smith & Nephew SNATS?

Smith & Nephew SNATS (NYSE:SNN) and Medline (NASDAQ:MDLN) are both large-cap medical equipment companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

25.6% of Smith & Nephew SNATS shares are held by institutional investors. 1.0% of Smith & Nephew SNATS shares are held by company insiders. Comparatively, 0.8% of Medline shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Medline had 10 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 11 mentions for Medline and 1 mentions for Smith & Nephew SNATS. Medline's average media sentiment score of 0.46 beat Smith & Nephew SNATS's score of 0.00 indicating that Medline is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Smith & Nephew SNATS
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Medline
2 Very Positive mention(s)
3 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Smith & Nephew SNATS has higher earnings, but lower revenue than Medline.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Smith & Nephew SNATS$6.16B2.07$625MN/AN/A
Medline$28.43B1.59N/AN/AN/A

Company Net Margins Return on Equity Return on Assets
Smith & Nephew SNATSN/A N/A N/A
Medline N/A N/A N/A

Smith & Nephew SNATS currently has a consensus price target of $30.93, suggesting a potential upside of 3.31%. Medline has a consensus price target of $50.54, suggesting a potential upside of 46.62%. Given Medline's stronger consensus rating and higher possible upside, analysts plainly believe Medline is more favorable than Smith & Nephew SNATS.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Smith & Nephew SNATS
0 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.50
Medline
1 Sell rating(s)
5 Hold rating(s)
22 Buy rating(s)
1 Strong Buy rating(s)
2.79

Summary

Medline beats Smith & Nephew SNATS on 6 of the 9 factors compared between the two stocks.

Get Medline News Delivered to You Automatically

Sign up to receive the latest news and ratings for MDLN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MDLN vs. The Competition

Export
MetricMedlineSurgical, Medical, And Dental Instruments And Supplies IndustryManufacturing SectorNASDAQ Exchange
Market Cap$43.60B$2.54B$4.30B$12.54B
Dividend YieldN/AN/A7.42%5.22%
P/E RatioN/A1.9021.6924.18
Price / Sales1.59372.36177.03112.26
Price / CashN/A3.5758.6057.13
Price / BookN/A6.5832.786.72
Net IncomeN/A-$69.38M$109.80M$337.19M
7 Day Performance-6.33%-4.90%-0.94%-0.75%
1 Month PerformanceN/AN/AN/A-1.69%
1 Year PerformanceN/A47.68%15.32%33.09%

Medline Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MDLN
Medline
3.7576 of 5 stars		$34.47
+3.9%		$50.54
+46.6%		N/A$43.60B$28.43BN/A43,000
GEHC
GE HealthCare Technologies
4.9318 of 5 stars		$63.16
-1.1%		$80.21
+27.0%		-12.8%$28.51B$20.98B14.9954,000
PHG
Koninklijke Philips
3.0636 of 5 stars		$26.45
-0.6%		N/A+11.1%$25.28B$17.64B22.5065,340
ZBH
Zimmer Biomet
4.5686 of 5 stars		$83.01
+0.5%		$102.80
+23.8%		-7.4%$15.97B$8.23B21.4517,000
SOLV
Solventum
2.8877 of 5 stars		$75.47
-0.6%		$84.25
+11.6%		+5.6%$12.99B$8.33B9.1920,000

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:MDLN) was last updated on 6/4/2026 by MarketBeat.com Staff.
From Our Partners
Nevada gold explorer near Kinross district draws attention
Gold has surged past $5,300 per ounce, with Goldman Sachs and JPMorgan forecasting $6,000+ by end of 2026. Cen...
Wall Street Logic | Sponsoredtc pixel
A gold storm is coming – are you ready?
The U.S. Treasury Secretary is betting big on gold - and the world's most successful investors are following s...
Traders Agency | Sponsoredtc pixel
Trump’s New Dollar revealed
The last time something like this happened was 1974 - a secret deal that quietly determined the financial fate...
Porter & Company | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
The SpaceX S-1 changes everything
SpaceX just filed its IPO paperwork. And buried inside that filing was something that should change how every ...
Crypto 101 Media | Sponsoredtc pixel
How to claim a stake in SpaceX before the June 12 IPO
SpaceX is expected to go public on June 12 - and for the first time, everyday investors may have a way in befo...
Brownstone Research | Sponsoredtc pixel
Oil is settling in yuan now - here's what that means for gold
Saudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...
Golden Portfolio | Sponsoredtc pixel
The chokepoint supplier behind SpaceX's $1.75 trillion empire
When Musk laughed and said 'you need transformers to run transformers,' it wasn't a joke - it was a confession...
Behind the Markets | Sponsoredtc pixel